专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

US20120136065A1 Treatment of CNS Disorders with trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine 有权
标题翻译：用反式4-（3,4-二氯苯基）-1,2,3,4-四氢-1-萘胺处理CNS紊乱
公开(公告)号：US20120136065A1
公开(公告)日：2012-05-31
申请号：US13365565
申请日：2012-02-03
申请人： Thomas P. JERUSSI , Qun Kevin FANG , Mark G. CURRIE
发明人： Thomas P. JERUSSI , Qun Kevin FANG , Mark G. CURRIE
IPC分类号： A61K31/135 , A61P25/28
CPC分类号： A61K31/135 , C07B2200/07 , C07C211/42 , C07C2602/10
摘要： Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.
摘要翻译：用（1R，4S） - 反式-4-（3,4-二氯苯基）-1,2,3,4-四氢-1-萘胺处理CNS障碍; 和（1S，4R） - 反式-4-（3,4-二氯苯基）-1,2,3,4-四氢-1-萘胺。还公开了制备4-（3,4-二氯苯基）-1,2,3,4-四氢-1-萘胺的方法。该方法包括制备N- [4-（3,4-二氯苯基）-1,2,3,4-四氢萘-1-基]甲酰胺的全部四种异构体，它们也是有用的。

22. 发明授权

US07456173B2 Compositions comprising zopiclone derivatives and methods of making and using the same 有权
标题翻译：包含佐匹克隆衍生物的组合物及其制备和使用方法
公开(公告)号：US07456173B2
公开(公告)日：2008-11-25
申请号：US11586896
申请日：2006-10-26
申请人： Thomas P. Jerussi , Qun K. Fang
发明人： Thomas P. Jerussi , Qun K. Fang
IPC分类号： A61K31/5377 , C07D413/14
CPC分类号： C07D487/04
摘要： The invention is directed to racemic and stereomerically pure compounds of Formula 3: and to pharmaceutical compositions comprising them, methods of their use, and methods of their preparation.
摘要翻译：本发明涉及外消旋和立体异构纯的式3化合物：以及包含它们的药物组合物，其使用方法及其制备方法。

23. 发明申请

US20080280993A1 Treatment of CNS Disorders With trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine 有权
标题翻译：用反式4-（3,4-二氯苯基）-1,2,3,4-四氢-1-萘胺处理中枢神经系统疾病
公开(公告)号：US20080280993A1
公开(公告)日：2008-11-13
申请号：US12173626
申请日：2008-07-15
申请人： Thomas P. Jerussi , Qun Kevin Fang , Mark G. Currie
发明人： Thomas P. Jerussi , Qun Kevin Fang , Mark G. Currie
IPC分类号： A61K31/136 , A61P25/28
CPC分类号： C07C211/42 , C07B2200/07 , C07C2602/10 , C07C2602/28
摘要： Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.
摘要翻译：用（1R，4S） - 反式-4-（3,4-二氯苯基）-1,2,3,4-四氢-1-萘胺处理CNS病症; 和（1S，4R） - 反式-4-（3,4-二氯苯基）-1,2,3,4-四氢-1-萘胺。还公开了制备4-（3,4-二氯苯基）-1,2,3,4-四氢-1-萘胺的方法。该方法包括制备N- [4-（3,4-二氯苯基）-1,2,3,4-四氢萘-1-基]甲酰胺的全部四种异构体，它们也是有用的。

24. 发明授权

US07105699B2 Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide 有权
公开(公告)号：US07105699B2
公开(公告)日：2006-09-12
申请号：US11220891
申请日：2005-09-07
申请人： Thomas P. Jerussi , Qun Kevin Fang , Mark G. Currie
发明人： Thomas P. Jerussi , Qun Kevin Fang , Mark G. Currie
IPC分类号： C07C211/45 , C07C233/15 , A61K31/135 , A61K31/03 , A61K31/165
CPC分类号： C07C211/42 , C07B2200/07 , C07C2602/10 , C07C2602/28
摘要： Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.

25. 发明授权

US07071234B2 Methods of treating or preventing erectile dysfunction 失效
标题翻译：治疗或预防勃起功能障碍的方法
公开(公告)号：US07071234B2
公开(公告)日：2006-07-04
申请号：US10395298
申请日：2003-03-25
申请人： Thomas P Jerussi , Chrisantha H. Senanayake , Qun K. Fang
发明人： Thomas P Jerussi , Chrisantha H. Senanayake , Qun K. Fang
IPC分类号： A61K31/136 , A61K31/44
CPC分类号： A61K45/06 , A61K31/11 , A61K31/135 , A61K31/137 , A61K2300/00
摘要： Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutramine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT3 antagonists.
摘要翻译：公开了用于治疗和预防疾病和病症的方法，包括但不限于勃起功能障碍，情感障碍，体重增加，脑功能障碍，疼痛，强迫症，药物滥用，慢性障碍，焦虑，进食障碍，偏头痛和失禁。所述方法包括施用多巴胺再摄取抑制剂和任选的另外的药理活性化合物。还公开了包含多巴胺再摄取抑制剂和任选的另外的药理学活性化合物的药物组合物和剂型。优选的多巴胺再摄取抑制剂是外消旋或光学纯的西布曲明代谢物及其药学上可接受的盐，溶剂化物和包合物。优选的额外的药理活性化合物包括影响中枢神经系统的药物，例如5-HT 3拮抗剂。

26. 发明授权

US06469008B2 (R)-hydroxynefazodone antipsychotic therapy 失效
标题翻译：（R） - 羟基吗啡酮抗精神病药治疗
公开(公告)号：US06469008B2
公开(公告)日：2002-10-22
申请号：US09992197
申请日：2001-11-14
申请人： Mark G. Currie , Thomas P. Jerussi , Paul D. Rubin
发明人： Mark G. Currie , Thomas P. Jerussi , Paul D. Rubin
IPC分类号： A61K3150
CPC分类号： A61K31/496 , C07D249/12
摘要： Treatment of psychoses with (R)-hydroxynefazodone is disclosed.
摘要翻译：公开了用（R） - 羟基吗唑酮治疗精神病。

27. 发明授权

US06333345B1 Methods of using and compositions comprising N-desmethylzolpidem 失效
标题翻译：使用方法和包含N-去甲基唑吡坦的组合物
公开(公告)号：US06333345B1
公开(公告)日：2001-12-25
申请号：US09563858
申请日：2000-05-04
申请人： Thomas P. Jerussi
发明人： Thomas P. Jerussi
IPC分类号： A61K31415
CPC分类号： A61K31/4439 , A61K31/437
摘要： The invention is directed to compositions comprising, and methods of using, N-desmethylzolpidem in the treatment and prevention of diseases and conditions in mammals. Examples of such diseases and conditions include, but are not limited to: sleep disorders such as insomnia; affective disorders such as depression, attention deficit disorder, and attention deficit disorder with hyperactivity or attention deficit/hyperactivity disorder; convulsive disorders such as epilepsy; anxiety; aggressive behavior; spasticity or acute muscle spasm; behavioral disorders; schizophrenia; and disorders associated with abnormal plasma hormone levels such as endocrine disorders.
摘要翻译：本发明涉及包含N-去甲基唑吡坦在治疗和预防哺乳动物疾病和病症中的组合物和使用方法。这些疾病和病症的实例包括但不限于：失眠症等睡眠障碍; 情绪障碍如抑郁症，注意力缺陷障碍，以及多动症或注意力缺陷/多动障碍的注意力缺陷障碍; 惊厥性疾病如癫痫; 焦虑; 侵略行为; 痉挛或急性肌肉痉挛; 行为障碍精神分裂症以及与异常血浆激素水平如内分泌紊乱相关的疾病。

28. 发明授权

US06254882B1 Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol 失效
标题翻译：使用光学纯（S） - 沙美特罗治疗肺部疾病的方法和组合物
公开(公告)号：US06254882B1
公开(公告)日：2001-07-03
申请号：US08931636
申请日：1997-09-16
申请人： Thomas P. Jerussi
发明人： Thomas P. Jerussi
IPC分类号： A61K970
CPC分类号： A61K9/008
摘要： A method and composition are disclosed utilizing the pure (S) isomer of salmeterol which is a potent bronchodilator with reduced adverse effects, having a better selectivity for &bgr;2 receptors than the corresponding R enantiomer or the racemate.
摘要翻译：公开了使用沙美特罗的纯（S）异构体的方法和组合物，其是有效的支气管扩张剂，其副作用降低，对β2受体的选择性优于相应的R对映异构体或外消旋体。

29. 发明授权

US4859685A Anesthetic composition and method of using the same 失效
标题翻译：麻醉成分及使用方法
公开(公告)号：US4859685A
公开(公告)日：1989-08-22
申请号：US896039
申请日：1986-08-13
申请人： Thomas P. Jerussi , John F. Capacchione , Mark J. Benvenga
发明人： Thomas P. Jerussi , John F. Capacchione , Mark J. Benvenga
IPC分类号： A61K31/445 , A61K45/06 , A61P21/02 , A61P23/00
CPC分类号： A61K31/445 , Y10S514/818
摘要： There is disclosed an injectable anesthetic pharmaceutical composition which does not exhibit muscle rigidity and which includes an anesthetic effective amount of at least one substituted N-(4-piperidinyl)-N-amide and a muscle rigidity inhibiting effective amount of at least one alpha-2 adrenergic agonist as principle ingredients. Also disclosed are methods of inducing and maintaining anesthesia without muscle rigidity by administering said composition to warm blooded animals.

30. 发明申请

US20080132578A1 Dosage forms of O-desmethylvenlafaxine 审中-公开
标题翻译： O-去甲基文拉法辛的剂量形式
公开(公告)号：US20080132578A1
公开(公告)日：2008-06-05
申请号：US12011083
申请日：2008-01-23
申请人： Thomas P. Jerussi , Chrisantha H. Senanayake , Nandkumar N. Bhongle
发明人： Thomas P. Jerussi , Chrisantha H. Senanayake , Nandkumar N. Bhongle
IPC分类号： A61K31/135
CPC分类号： C07D295/192 , A61K9/2054 , A61K9/2059 , A61K9/4866 , A61K31/135 , C07C215/64 , C07C217/74 , C07C233/18 , C07C255/36 , C07C255/37 , C07C2601/14
摘要： Methods of preparing, and compositions comprising, derivatives of venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.
摘要翻译：公开了制备方法和包含文拉法辛衍生物的组合物。还公开了治疗和预防疾病和病症的方法，包括但不限于情感障碍如抑郁，双相和躁狂症，注意力缺陷障碍，具有多动症的注意缺陷障碍，帕金森病，癫痫，脑功能障碍，肥胖症和体重增加，失禁，痴呆和相关疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式